Viridian Therapeutics won FDA approval for Lumvoa (veligrotug-vvze), an IGF-1R antagonist for thyroid eye disease, clearing the way for competition with Amgen’s Tepezza. The FDA clearance covers both active and chronic phases, and Viridian said it will launch the therapy immediately. Analysts highlighted that Lumvoa’s label includes broadly similar safety language to Tepezza and that the program supported statistically significant effects in diplopia response and complete diplopia resolution across disease phases. For the TED market, the approval adds a second mechanism-targeted option in a category where payer dynamics and real-world tolerability will likely shape uptake.